Systemic Lupus Erythematosus Monitoring Guidelines

Introduction to SLE Monitoring

The European League Against Rheumatism recommends that patients with SLE require structured monitoring at every visit for disease activity using a validated index, with annual organ damage assessment, and at least yearly cardiovascular risk factor screening, complemented by laboratory monitoring including anti-dsDNA, complement levels, renal function tests, and complete blood counts 1, 2

Disease activity assessment is mandatory at every visit using a validated instrument such as SLEDAI, BILAG, or SLE-DAS to quantify current disease status and guide treatment decisions 2
Quality of life evaluation should be performed through patient history and/or a 0-10 visual analog scale (patient global score) at each encounter 1, 2
Assessment of comorbidities and drug toxicity must occur at every visit to identify treatment-related complications early 1, 2

Organ damage evaluation is required annually to detect irreversible changes from disease or treatment, which impacts long-term prognosis and mortality 1, 2

Clinical assessment: smoking status, history of cerebral/cardiovascular events, physical activity level, oral contraceptive or hormonal therapy use, and family history of cardiovascular disease 1, 4, 5
Laboratory tests: fasting lipid panel (cholesterol) and glucose 1, 4, 5
Physical examination: blood pressure measurement and body mass index (and/or waist circumference) 1, 4, 5
Patients on glucocorticoids require more frequent cardiovascular monitoring due to accelerated risk 1, 4, 5

Complete blood count (CBC): to detect cytopenias, which predict infection risk and disease progression 6
Inflammatory markers: ESR and CRP (noting that CRP >50 mg/L suggests superimposed infection) 6
Renal function: serum creatinine, serum albumin, urinalysis, and urine protein-to-creatinine ratio 6
Serologic markers: anti-dsDNA antibodies and complement levels (C3, C4) 6

Serum creatinine, urine sediment analysis, proteinuria, and blood pressure have predictive value for renal flares and outcomes 6
Skin biopsy is recommended if lesion morphology changes or treatment fails, as many conditions mimic lupus-specific lesions 6
Consider using the Cutaneous Lupus Disease Area and Severity Index (CLASI) in patients with predominant skin manifestations to quantify disease activity and damage 6

Assess calcium and vitamin D intake, exercise habits, and smoking status at each visit 1, 4, 5
Screen for osteoporosis according to standard guidelines for postmenopausal women and all patients on glucocorticoids or medications reducing bone mineral density 1, 4, 5
Prescribe calcium and vitamin D supplementation for all patients on chronic glucocorticoid therapy 3
Screen for HIV based on patient risk factors 1, 5
Screen for hepatitis B and C based on risk factors, particularly before initiating immunosuppressive drugs including high-dose glucocorticoids 5
Tuberculosis screening according to local guidelines, especially before immunosuppression 5
Follow general population guidelines, including cervical smear tests, with particular attention to cervical cancer surveillance 1, 4, 5

Do not rely on serological activity alone without clinical correlation, as this risks overtreatment and unnecessary medication escalation 3
Avoid prolonged high-dose glucocorticoids due to increased infection risk, osteoporosis, avascular necrosis, and cardiovascular complications 3
Recognize that CRP elevation >50 mg/L warrants infection workup rather than assuming lupus flare alone 6